secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001326732-25-000028
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor Q4 net loss widens to $45.6M; full-year revenue falls 37% to $110.5M
---------------------------------------------------------------------------

- Q4 revenue $52.8M (+3.5% YoY) driven by milestone payments; full-year revenue $110.5M vs $174.6M.
- FY 2024 net loss $232.6M ($3.58 diluted EPS) vs $133.1M ($2.20); R&D spend dropped to $227.7M.
- Cash $706.7M at Dec 31; 2025 guidance $535-585M, runway into 2028.
- Pipeline: XmAb942 healthy-volunteer data 1H 2025; XmAb819 ccRCC data 2H 2025; plamotamab RA Ph1b/2a start 1H 2025.
- Vudalimab development paused; milestone revenue of $30M (Amgen) and $4M (Novartis) received in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000028/0001326732-25-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000028/xncr-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001326732-25-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer